EGFR and non-small cell lung carcinoma: In the KEYNOTE-789 study, addition of pembrolizumab to chemotherapy in patients with TKI-resistant, EGFR mutant, metastatic nonsquamous NSCLC did not significantly prolong PFS or OS versus placebo plus chemotherapy [34].